{
    "info": {
        "nct_id": "NCT06868277",
        "official_title": "A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)",
        "inclusion_criteria": "* Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes.\n* Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.\n* Absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) rearrangements. Negative assay result is required for all non-squamous histology subtypes.\n* Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L (first line) therapies.\n* WHO (World Health Organization)/ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization.\n* Minimum life expectancy of 12 weeks.\n* Provision of acceptable tumor sample for the central testing prior to randomization.\n* At least one lesion not previously irradiated that qualifies as a RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, Version 1.1) TL (target lesion) at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT (computed tomography) or MRI (magnetic resonance imaging) and is suitable for accurate repeated measurements.\n* Adequate organ and bone marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* As judged by the investigator, any severe or uncontrolled systemic diseases, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.\n* History of organ transplant.\n* Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.\n* History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.\n* Presence of small cell and neuroendocrine histology components.\n* Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 4 weeks prior to start of study intervention.\n* Active primary immunodeficiency/active infectious disease(s)\n* Active tuberculosis infection\n* Any prior systemic therapy received for advanced or mNSCLC (metastatic non-small cell lung cancer).\n* Any prior exposure to an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.\n* Any prior treatment with an anti-PD-1 (programmed cell death protein 1) or anti-PD-L1 (anti-programmed death-ligand 1) agent.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Minimum life expectancy of 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Minimum life expectancy of 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one lesion not previously irradiated that qualifies as a RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, Version 1.1) TL (target lesion) at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT (computed tomography) or MRI (magnetic resonance imaging) and is suitable for accurate repeated measurements.",
            "criterions": [
                {
                    "exact_snippets": "At least one lesion not previously irradiated",
                    "criterion": "lesion irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "previous irradiation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "qualifies as a RECIST 1.1 ... TL (target lesion) at baseline",
                    "criterion": "RECIST 1.1 target lesion status",
                    "requirements": [
                        {
                            "requirement_type": "RECIST 1.1 target lesion qualification",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm)",
                    "criterion": "lesion size",
                    "requirements": [
                        {
                            "requirement_type": "longest diameter (non-lymph node)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "short axis (lymph node)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with CT (computed tomography) or MRI (magnetic resonance imaging)",
                    "criterion": "imaging modality for measurement",
                    "requirements": [
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "CT",
                                "MRI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "suitable for accurate repeated measurements",
                    "criterion": "suitability for repeated measurement",
                    "requirements": [
                        {
                            "requirement_type": "suitability for repeated measurement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L (first line) therapies.",
            "criterions": [
                {
                    "exact_snippets": "Absence of documented tumor genomic mutation results ... in any other actionable driver oncogenes for which there are locally approved targeted 1L (first line) therapies",
                    "criterion": "tumor genomic mutation in actionable driver oncogenes with locally approved targeted 1L therapies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "testing_status",
                            "expected_value": "tested as part of standard local practice"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically documented NSCLC (non small lung cancer)",
                    "criterion": "NSCLC diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologically documented",
                                "cytologically documented"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "including all histological subtypes",
                    "criterion": "NSCLC histological subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype_inclusion",
                            "expected_value": "all"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and bone marrow function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ ... function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provision of acceptable tumor sample for the central testing prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Provision of acceptable tumor sample for the central testing prior to randomization.",
                    "criterion": "tumor sample",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "acceptability for central testing",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) rearrangements. Negative assay result is required for all non-squamous histology subtypes.",
            "criterions": [
                {
                    "exact_snippets": "Absence of sensitizing EGFR (epidermal growth factor) mutations",
                    "criterion": "sensitizing EGFR mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Absence of ... ALK (anaplastic lymphoma kinase) ... rearrangements",
                    "criterion": "ALK rearrangements",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Absence of ... ROS1 (c-ros oncogene 1) rearrangements",
                    "criterion": "ROS1 rearrangements",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Negative assay result is required for all non-squamous histology subtypes",
                    "criterion": "assay result for EGFR, ALK, and ROS1 in non-squamous histology subtypes",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* WHO (World Health Organization)/ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "WHO (World Health Organization)/ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1",
                    "criterion": "WHO/ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization",
                    "criterion": "WHO/ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "deterioration",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "previous 2 weeks prior to baseline at screening and prior to randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.",
            "criterions": [
                {
                    "exact_snippets": "Stage IV mNSCLC (metastatic non-small cell lung cancer)",
                    "criterion": "non-small cell lung cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage IV mNSCLC (metastatic non-small cell lung cancer)",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "metastatic non-small cell lung cancer"
                        }
                    ]
                },
                {
                    "exact_snippets": "(based on the American Joint Committee on Cancer Edition 8)",
                    "criterion": "staging system",
                    "requirements": [
                        {
                            "requirement_type": "system",
                            "expected_value": "American Joint Committee on Cancer Edition 8"
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to curative treatment",
                    "criterion": "curative treatment amenability",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "History of organ transplant.",
                    "criterion": "organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis infection",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis infection",
                    "criterion": "tuberculosis infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active or prior documented autoimmune or inflammatory disorders",
                    "criterion": "autoimmune or inflammatory disorders",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "prior documented"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring chronic treatment with steroids or other immunosuppressive treatment",
                    "criterion": "chronic treatment with steroids or other immunosuppressive treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active primary immunodeficiency/active infectious disease(s)",
            "criterions": [
                {
                    "exact_snippets": "Active primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active infectious disease(s)",
                    "criterion": "infectious disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of small cell and neuroendocrine histology components.",
            "criterions": [
                {
                    "exact_snippets": "Presence of small cell ... histology components",
                    "criterion": "small cell histology component",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... neuroendocrine histology components",
                    "criterion": "neuroendocrine histology component",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior exposure to an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.",
            "criterions": [
                {
                    "exact_snippets": "Any prior exposure to an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) therapy",
                    "criterion": "prior exposure to anti-TIGIT therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any other anticancer therapy targeting immune-regulatory receptors or mechanisms",
                    "criterion": "prior exposure to anticancer therapy targeting immune-regulatory receptors or mechanisms",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 4 weeks prior to start of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 4 weeks prior to start of study intervention.",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        },
                        {
                            "requirement_type": "steroid requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "anticonvulsant requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration without steroids or anticonvulsants",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior treatment with an anti-PD-1 (programmed cell death protein 1) or anti-PD-L1 (anti-programmed death-ligand 1) agent.",
            "criterions": [
                {
                    "exact_snippets": "Any prior treatment with an anti-PD-1 (programmed cell death protein 1) or anti-PD-L1 (anti-programmed death-ligand 1) agent.",
                    "criterion": "prior treatment with anti-PD-1 or anti-PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "anti-PD-1",
                                "anti-PD-L1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* As judged by the investigator, any severe or uncontrolled systemic diseases, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.",
            "criterions": [
                {
                    "exact_snippets": "any severe or uncontrolled systemic diseases",
                    "criterion": "systemic diseases",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "makes it undesirable for the participant to participate in the study",
                    "criterion": "suitability for study participation",
                    "requirements": [
                        {
                            "requirement_type": "desirability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "would jeopardize compliance with the protocol",
                    "criterion": "ability to comply with protocol",
                    "requirements": [
                        {
                            "requirement_type": "compliance risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.",
            "criterions": [
                {
                    "exact_snippets": "History of another primary malignancy",
                    "criterion": "history of another primary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence",
                    "criterion": "prior malignancy (other than index cancer)",
                    "requirements": [
                        {
                            "requirement_type": "treatment intent",
                            "expected_value": "curative"
                        },
                        {
                            "requirement_type": "active disease status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "disease-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "risk of recurrence",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior systemic therapy received for advanced or mNSCLC (metastatic non-small cell lung cancer).",
            "criterions": [
                {
                    "exact_snippets": "Any prior systemic therapy received for advanced or mNSCLC (metastatic non-small cell lung cancer)",
                    "criterion": "prior systemic therapy for advanced or mNSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}